Eli Lilly and Co. and Immunocore have entered into an immunotherapy-based clinical collaboration to explore Immunocore’s lead T cell receptor-based investigational therapeutic, IMCgp100, in combination with Lilly’s galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma. The collaboration aims to identify combination regimens that provide synergies in efficacy and durability in patients with metastatic cutaneous and uveal melanomas. Immunocore and Lilly wi...